AURA — Aura Biosciences, Inc. stock price, charts and financials

QT47Aura Biosciences, Inc.

Aura Biosciences, Inc. (NASDAQ: AURA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
6.59
-0.14-2.08%
OverviewShort InterestFilings
AURAQT47Aura Biosciences, Inc.·NASDAQ
6.59-2.08%
News
Down 2.1% — Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript (seekingalpha.com).
Medium confidence
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MESO+3.19%$14.87FTRE+1.55%$20.28NKTR+1.45%$68.36GHRS+3.50%$28.72RAPP+1.35%$41.95AGIO+2.00%$33.61ZBIO-1.08%$31.97GPCR-1.13%$35.10
Snapshot
Index-P/E-EPS (ttm)-Insider Own18.23%Shs Outstand103.44MPerf Week-5.72%
Market Cap681.65MForward P/E-EPS next Y-1.52Insider Trans-36.84%Shs Float64.51MPerf Month-19.24%
Enterprise Value370.65MPEG-EPS next Q-0.37Inst Own-Short Float9.62%Perf Quarter4.44%
Income-106.00MP/S0.00EPS this Y-Inst Trans-Short Ratio9.46Perf Half Y0.15%
Sales0.00P/B2.16EPS next Y8.84%ROA-37.63%Short Interest6.20MPerf YTD20.92%
Book/sh3.05P/C2.10EPS next 5Y-ROE-73.18%52W High9.54 -30.92%Perf Year4.77%
Cash/sh3.13P/FCF-EPS past 3/5Y-ROIC-41.61%52W Low4.73 39.32%Perf 3Y-35.46%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.00% 4.85%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM0.00%Oper. Margin0.00%ATR (14)0.37Perf 10Y-
Dividend Ex-Date-Quick Ratio16.82Sales Y/Y TTM-Profit Margin0.00%RSI (14)32.46Recom2.00
Dividend Gr. 3/5Y-Current Ratio16.82EPS Q/Q-2.13%SMA20-10.32%Beta1.08Target Price17.50
Payout0.00%Debt/Eq0.10Sales Q/Q-SMA50-9.89%Rel Volume1.34Prev Close6.73
Employees113LT Debt/Eq0.10EarningsNov 12SMA200-0.83%Avg Volume684.53KPrice6.59
IPO DateOct 29, 2021Option/ShortYes / YesEPS/Sales Surpr.-28.00% -Net Debt/EBITDA0.39Volume916,367Change-2.08%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-11-26ReiteratedHC Wainwright & Co.Buy$25 → $18
May-12-26ReiteratedLeerink Partners$26 → $17
Mar-26-25ReiteratedJMP SecuritiesMarket Outperform$19
Mar-25-25ReiteratedHC Wainwright & Co.Buy$22 → $25
Mar-24-25ReiteratedHC Wainwright & Co.Buy$22 → $25
Oct-18-24ReiteratedScotiabankSector Outperform$23
Oct-18-24ReiteratedBTIGBuy$24
Oct-18-24ReiteratedHC Wainwright & Co.Buy$21 → $22
Jul-25-24InitiatedH.CBuy$21
Nov-11-22ReiteratedJMP SecuritiesMarket Outperform
Latest News· Times ET
Sep-16-26
Sep-16-2603:31PM
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com
Sep-07-26
Sep-07-2612:20AM
Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.defenseworld.net
Sep-06-26
Sep-06-2611:06AM
Is Aura Investments (TASE:AURA) Fully Valued As Mixed Earnings And A New Dividend Stir Interest?Yahoo
Sep-02-26
Sep-02-2612:01PM
Aura Biosciences to Participate in Upcoming Investor Conferenceglobenewswire.com
Sep-01-26
Sep-01-2611:52PM
BlackRock Inc. Makes New Investment in Aura Biosciences, Inc. $AURAdefenseworld.net
12:28PM
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Aug-26-26
Aug-26-2612:20AM
ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURAdefenseworld.net
Aug-12-26
Aug-12-2611:22AM
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approvalseekingalpha.com
Jul-24-26
Jul-24-2604:04AM
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga
Jul-08-26
Jul-08-2603:01AM
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directorsglobenewswire.com
Company

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000————
Cost of Goods Sold Incl. D&A001————
Gross Profit00-1————
Selling, General and Administrative Excl. Other222320————
Research and Development907364————
Other Operating Expense100————
Operating Income-113-96-85————
Interest Expense
000————
Unusual Expense
———————
Non-Operating Income (Expense)799————
Net Income Before Taxes-106-87-76————
Income Taxes
000————
Consolidated Net Income-106-87-76————
Net Income From Continuing Operations-106-87-76————
Net Income-106-87-76————
EPS (Recurring)-1.76-1.75-1.93————
EPS (Basic, Before Extraordinaries)-1.76-1.75-1.93————
EPS (Diluted)-1.76-1.75-1.93————
EBITDA-105-86-75————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding605040————
Market Capitalization327411354————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$9.49$8.21$6.93$5.66$4.38● Close Price0.00M9.76M19.52M29.28M39.04MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Gibney Anthony SSee RemarksJun 16 '26Sale6.4212,82482,330265,354Jun 16
Matrix Capital Management Company, LP10% OwnerMay 07 '26Sale5.646,922,87039,044,9870May 11
Kilroy ConorSee RemarksApr 16 '26Sale7.0211,73882,401217,835Apr 16
Kilroy ConorSee RemarksFeb 17 '26Sale5.0512,07960,999167,234Feb 17
Plavsic MarkChief Technology OfficerFeb 17 '26Sale5.0515,89080,245181,397Feb 17
Hopkins Janet JillChief Medical OfficerFeb 17 '26Sale5.0620,401103,229232,284Feb 17
Elazzouzi AmySenior Vice President, FinanceFeb 17 '26Sale5.068,54943,25875,532Feb 17
de los Pinos ElisabetSee RemarksFeb 17 '26Sale5.0647,648241,099409,815Feb 17
Elazzouzi AmySenior Vice President, FinanceJan 20 '26Sale4.861,5817,68484,081Jan 20
de los Pinos ElisabetSee RemarksJan 20 '26Sale4.8616,92882,270457,463Jan 20
Hopkins Janet JillChief Medical OfficerNov 17 '25Sale5.4217,10992,731252,685Nov 17
Elazzouzi AmySenior Vice President, FinanceOct 29 '25Sale6.358965,69085,662Oct 29
de los Pinos ElisabetSee RemarksOct 29 '25Sale6.359,04957,461474,391Oct 29
Plavsic MarkChief Technology OfficerOct 16 '25Sale6.3512,16977,273197,287Oct 16
Elazzouzi AmySenior Vice President, FinanceAug 18 '25Option Exercise3.9612,89951,10494,280Aug 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.